Page last updated: 2024-08-25

bendamustine hydrochloride and Radiodermatitis

bendamustine hydrochloride has been researched along with Radiodermatitis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abe, R; Amagai, M; Funakoshi, T; Kikuchi, T; Koda, Y; Kurihara, Y; Mori, T; Okamoto, S; Sato, H; Shimizu, T; Tsunoda, K; Yamagami, J	1

Other Studies

1 other study(ies) available for bendamustine hydrochloride and Radiodermatitis

Article	Year
Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus. Annals of hematology, 2017, Volume: 96, Issue:7 Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lymphoma, Follicular; Neoplasm Grading; Neoplasm Recurrence, Local; Paraneoplastic Syndromes; Pemphigus; Radiodermatitis; Rituximab; Severity of Illness Index; Skin; Treatment Outcome; Tumor Burden	2017

Article

Year

Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus.

Annals of hematology, 2017, Volume: 96, Issue:7

Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Bendamustine Hydrochloride; Combined Modality Therapy; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunologic Factors; Lymphoma, Follicular; Neoplasm Grading; Neoplasm Recurrence, Local; Paraneoplastic Syndromes; Pemphigus; Radiodermatitis; Rituximab; Severity of Illness Index; Skin; Treatment Outcome; Tumor Burden

2017